Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 6868-year-old man presents to an urgent care clinic with an expanding, warm, and erythematous rash on his left lower extremity. He has a medical history significant for a mechanical mitral valve replacement performed four years ago, for which he takes daily warfarin. His most recent International Normalized Ratio (INR) was 3.13.1 two days ago (target range 2.52.5 to 3.53.5). The physician diagnoses purulent cellulitis and prescribes a 77-day course of oral trimethoprim-sulfamethoxazole. Which of the following actions are the most appropriate next steps in the management of this patient's anticoagulation? (Select 2 answers)

  1. Pre-emptively reduce the weekly dose of warfarin by 25%25\% to 50%50\%Answer
  2. Schedule a follow-up International Normalized Ratio (INR) test in 33 to 55 daysAnswer
  3. C
    Pre-emptively increase the weekly dose of warfarin by 25%25\% to 50%50\%
  4. D
    Measure the baseline activated partial thromboplastin time (aPTT) prior to starting the antibiotic
  5. E
    Discontinue the warfarin for the duration of the antibiotic therapy

Answer

The correct management includes pre-emptively reducing the weekly dose of warfarin by 25%25\% to 50%50\% and scheduling a follow-up INR test in 33 to 55 days.
Trimethoprim-sulfamethoxazole strongly inhibits the cytochrome P450 2C9 (CYP2C9) isoenzyme, which is responsible for clearing the more potent S-enantiomer of warfarin. Additionally, the antibiotic eliminates intestinal flora that produce vitamin K, further intensifying the anticoagulant effect. When initiating this specific antibiotic in a patient stabilized on warfarin, standard medical guidelines mandate an immediate, pre-emptive dose reduction of the warfarin by 25%25\% to 50%50\%. Because the interaction takes time to alter the steady-state degradation of coagulation factors (particularly Factor II), the International Normalized Ratio (INR) must be closely monitored and rechecked within 33 to 55 days to ensure the patient remains within the target therapeutic window and to guide any further necessary dosing adjustments.

Step-by-Step Solution

1
Identify the pharmacokinetic interaction between the patient's baseline medication (warfarin) and the newly prescribed medication (trimethoprim-sulfamethoxazole).
Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 2C9 (CYP2C9) enzyme.
CYP2C9 metabolizes the highly active S-enantiomer of warfarin. Inhibition leads to decreased clearance, accumulating levels, and elevated INR.
2
Determine the necessary treatment modification to mitigate the interaction risk.
The warfarin dose must be empirically reduced by 25%25\% to 50%50\%.
Without pre-emptive reduction, the patient is at profound risk for hemorrhagic complications due to the prolonged half-life of the active drug.
3
Establish the correct monitoring parameter and appropriate time interval for re-evaluation.
Order an INR test in 33 to 55 days.
It takes several days for the alteration in factor synthesis to be reflected in the INR. Checking it at 33 to 55 days detects the peak effect of the interaction and allows for further safe titration.

Key Concept

Monitoring and dose adjustment for pharmacokinetic interactions with high-risk anticoagulants.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic